Welcome to HitGen

Pipeline

HitGen is focusing our innovative ability on discovering novel therapies that will make a real difference to patients with cancer or Inflammatory diseases. We have developed a broad and deep pipeline of both wholly owned and partnered therapeutics candidates. Our pipeline includes both small molecule and nucleic acid drug drugs.

Small molecule drug pipeline

Cancer
Projects
Indication
Hit Optimization
Lead Optimization
Preclinical Study
IND Filing
Clinical Trails
HG146

Selective HDAC inhibitor, capsule

Multiple myeloma
HG146

Selective HDAC inhibitor, capsule

Solid tumor
HG030

2nd generation NTRK/ROS1 inhibitor, tablet

Solid tumor
HG381

Immuno-oncology agonist

Cancer
HGT01

Tumor immunology(FIC)

Cancer
HGT02

Tumor immunology(FIC)

Cancer
HGT03

Protein degrader(FIC)

Cancer
HGT04

Transcriptomics(FIC)

Cancer
HGT05

Kinase inhibitor(FIC)

Liver Cancer
Inflammation
HGP0508

Small molecule for anti-inflammatory therapeutics (FIC)

Inflammation
Others
HGC245

Kinase inhibitor

Glaucoma

Nucleic acid drug pipeline

Tumor
Projects
Indication
Original siRNA Design and Screening
Hit siRNA Optimization
Lead siRNA Confirm
Preclinical Study
IND Filing
Clinical Trails
HGP2142

TGF-β1 specific siRNA drug

Liver Cancer
HGN001

Nucleic acid drug for specific mutation of cancer target

Solid tumor
HGN002

Undisclosed

Solid tumor

Note: Several early projects are not shown. FIC,first-in-class;BIC,best-in-class

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information